609 related articles for article (PubMed ID: 20570444)
1. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
Siemann DW
Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444
[TBL] [Abstract][Full Text] [Related]
2. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
Siemann DW; Chaplin DJ; Horsman MR
Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Gevertz JL
Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
[TBL] [Abstract][Full Text] [Related]
4. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
5. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
6. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman MR; Bohn AB; Busk M
Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
[TBL] [Abstract][Full Text] [Related]
7. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
8. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
9. Vascular disrupting agents (VDAs) in anticancer therapy.
Daenen LG; Roodhart JM; Shaked Y; Voest EE
Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
[TBL] [Abstract][Full Text] [Related]
10. Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy.
Iga AM; Sarkar S; Sales KM; Winslet MC; Seifalian AM
Cancer Res; 2006 Dec; 66(24):11517-9. PubMed ID: 17178842
[TBL] [Abstract][Full Text] [Related]
11. Vascular-disrupting agents in oncology.
Mita MM; Sargsyan L; Mita AC; Spear M
Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
13. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of the tumour vasculature.
Chan LS; Daruwalla J; Christophi C
ANZ J Surg; 2008 Nov; 78(11):955-67. PubMed ID: 18959693
[TBL] [Abstract][Full Text] [Related]
15. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
17. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
Spear MA; LoRusso P; Mita A; Mita M
Curr Drug Targets; 2011 Dec; 12(14):2009-15. PubMed ID: 21777190
[TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Liang W; Ni Y; Chen F
Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
[TBL] [Abstract][Full Text] [Related]
19. Vascular disrupting agents in cancer therapy.
Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular toxicity profiles of vascular-disrupting agents.
Subbiah IM; Lenihan DJ; Tsimberidou AM
Oncologist; 2011; 16(8):1120-30. PubMed ID: 21742963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
